Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares Bought by Trust Co. of Toledo NA OH

Trust Co. of Toledo NA OH raised its holdings in Ocuphire Pharma, Inc. (NASDAQ:OCUPFree Report) by 24.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 32,399 shares of the company’s stock after acquiring an additional 6,399 shares during the quarter. Trust Co. of Toledo NA OH owned 0.15% of Ocuphire Pharma worth $141,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of OCUP. Rice Hall James & Associates LLC lifted its holdings in Ocuphire Pharma by 9.5% in the first quarter. Rice Hall James & Associates LLC now owns 145,026 shares of the company’s stock valued at $470,000 after acquiring an additional 12,593 shares during the period. Bank of Montreal Can purchased a new stake in shares of Ocuphire Pharma in the 1st quarter worth about $68,000. Kestra Private Wealth Services LLC acquired a new stake in Ocuphire Pharma in the 1st quarter valued at about $32,000. Renaissance Technologies LLC purchased a new position in Ocuphire Pharma during the 2nd quarter valued at about $381,000. Finally, Millennium Management LLC acquired a new position in Ocuphire Pharma during the second quarter worth about $68,000. Institutional investors and hedge funds own 17.37% of the company’s stock.

Analysts Set New Price Targets

OCUP has been the subject of several research reports. Cantor Fitzgerald restated an “overweight” rating and set a $17.00 price objective on shares of Ocuphire Pharma in a research report on Monday, August 14th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Ocuphire Pharma in a research note on Monday, August 14th.

Read Our Latest Research Report on Ocuphire Pharma

Ocuphire Pharma Price Performance

OCUP opened at $4.01 on Friday. Ocuphire Pharma, Inc. has a 12 month low of $1.90 and a 12 month high of $6.60. The stock has a market capitalization of $84.25 million, a price-to-earnings ratio of 4.77 and a beta of 0.31. The business has a 50-day moving average of $4.04 and a two-hundred day moving average of $4.29.

Ocuphire Pharma (NASDAQ:OCUPGet Free Report) last announced its earnings results on Friday, August 11th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.01). The company had revenue of $3.67 million during the quarter. Equities research analysts anticipate that Ocuphire Pharma, Inc. will post -0.6 earnings per share for the current year.

Ocuphire Pharma Company Profile

(Free Report)

Ocuphire Pharma, Inc, a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate for dim light or night vision disturbances; and for pharmacologically induced mydriasis and presbyopia.

Featured Articles

Institutional Ownership by Quarter for Ocuphire Pharma (NASDAQ:OCUP)

Receive News & Ratings for Ocuphire Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocuphire Pharma and related companies with MarketBeat.com's FREE daily email newsletter.